Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab + Androgen Ablation in Advanced Prostate Cancer
NCT00170157Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Jun 2004
- Primary completion
- Apr 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ipilimumab in prostate cancer (PCa) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Progression-Free Survival at 18 months. Started Jun 2004; status: completed.
02
Drugs
ipilimumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00170157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00170157.